Savara (SVRA) stock is in focus after the company reported a Q1 2026 net loss of US$37.3 million and highlighted key regulatory milestones and funding plans tied to its lead drug candidate MOLBREEVI.

The share price has pulled back recently, with a 1‑month share price return of down 14.31% and a year to date share price return of down 10.82%. However, the 1‑year total shareholder return of 63.84% and 5‑year total shareholder return of 194.15% point to momentum that has built over a longer horizon as investors react to regulatory progress and financing plans around MOLBREEVI.

If you are weighing Savara against other opportunities in healthcare, this could be a good moment to scan for companies riding similar themes in 32 healthcare AI stocks

With the stock down in the short term but showing strong multi year returns, and with MOLBREEVI moving through key regulatory steps, the real question is whether this pullback signals an opportunity or if the market already prices in future growth.

Preferred Price to Book Multiple of 7.2x: Is it justified?

The current picture suggests Savara trades on a richer valuation than many peers, with the stock carrying a price to book ratio of 7.2x alongside ongoing losses.

The P/B ratio compares the market value of the equity to its book value, which can be a useful guide for asset heavy or early stage companies with limited revenue. For Savara, this matters because the company reports a loss of $129.48 million and makes less than $1 million in revenue, so traditional earnings based metrics like P/E are not meaningful right now.

According to Simply Wall St, Savara is considered expensive on this basis, with a P/B of 7.2x compared both to the US Biotechs industry average of 2.4x and a peer average of 3.4x. That kind of premium suggests the market is assigning substantial value to Savara's future revenue and profit forecasts, including expectations that revenue could grow 54.9% per year and that earnings are forecast to grow 64.99% per year as the company moves toward profitability over the next three years.

When you set Savara's 7.2x side by side with industry and peer levels, the gap is clear and not marginal. The stock's valuation sits at roughly three times the wider US Biotechs industry average and more than double the peer group, which underlines how much optimism is already reflected in the share price relative to companies with lower P/B multiples.

Result: Price to book ratio of 7.2x (OVERVALUED)

However, the story can change quickly if MOLBREEVI hits regulatory setbacks or if ongoing net losses of US$129.48 million make future funding more difficult on current terms.

Next Steps

With both optimism around MOLBREEVI and concern about ongoing losses in play, it makes sense to review the details yourself and decide where you stand, then weigh the 1 key reward and 2 important warning signs

Looking for more investment ideas?

Once you have formed a view on Savara, do not stop there. Use this moment to scan other opportunities that might fit your goals just as well.

• Target potential bargains by checking companies that score well on quality and valuation through the 50 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks highlighted in the 66 resilient stocks with low risk scores that focus on steadier risk profiles.
• Hunt for lesser known opportunities by scanning the screener containing 22 high quality undiscovered gems that spotlight companies with strong fundamentals but limited attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.